Skip to main content

Table 2 Effectiveness of the trivalent influenza 2011–12 vaccine against influenza A(H3N2) in target group for vaccination by age group, according to the time since vaccination, cycEVA study (weeks 52/2011 – 14/2012), Spain

From: Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011–2012 season in Spain, among population targeted for vaccination

Study population

Time since vaccination

Cases and controls (N/N)

Vaccinated cases and controls (N/N)

OR

Influenza VE % (95% CI)

Trend p valuec

≥65 years

49–88 days

39/17

4/7

Crude

84 (33;96)

0.211

Adjusted

85 (18;97)a

89–127 days

72/24

37/14

Crude

24 (−92;70)

Adjusted

33 (−102;78)a

128–166 days

58/14

23/4

Crude

−64 (−487;54)

Adjusted

−376 (−4332;49)a

<65 years

39–75 days

104/64

1/4

Crude

85 (−33;98)

0.335

Adjusted

84 (−138;99)b

76–111 days

114/66

11/6

Crude

−7 (−203;62)

Adjusted

19 (−149;73)b

112–148 days

113/71

10/11

Crude

47 (−32;79)

Adjusted

58 (−19;86)b

  1. aModel adjusted for age groups (65–75, 76–85, 86–95 and 95–105 years), and week of swabbing. bModel adjusted for age groups (0–4, 5–14, 15–44 and 45–64 years), and week of swabbing. cTest for trend using time since vaccination as continuous.